News & Views

Rising awareness and emergence of differentiated solutions for multiple psychiatric and mental health conditions is an ongoing theme of innovation in pharma but also adjacent and “convergence” fields in healthcare. Increasing incidence, certainly exacerbated by lockdowns and other measures implemented to curtail the spread of COVID-19, and the significant lack of innovation in the past represent the key ingredients for a resurgence, which is currently emerging.
Capital allocation towards innovative health-tech solutions has fuelled an increase in adoption of digital technologies. We outline a few current themes and future trends in the area.
A month into 2022 and all virtual “JPM meetings” completed, we took a moment to reflect on the past
The UK Government and EU Commission trumpeted their last minute Brexit trade deal, struck at the end of December, as comprehensive, the biggest yet. Even allowing for the hyperbole of politicians, a closer inspection of the EU-UK Trade and Cooperation Agreement (TCA) renders these statements illusory for the pharma sector. In this article we summarise the extent to which the TCA really assists businesses in the sector to overcome the separation of the UK and the EU into two separate markets:
The start of a new year in healthcare has over the past decades been characterized by back-to-back meetings spread across hotel rooms in San Francisco where the industry’s annual gathering had taken place, not to say had been celebrated. Nobody knows if or when we will return to holding physical meetings. What the pandemic has shown us all is that a lot of time can be saved when interacting virtually:
As what used to be healthcare’s busiest meetings week is going to be a week of virtual interaction around the globe, we thought it worthwhile to share a few considerations on partnering between biotech and large pharma from the perspective of the developing biotech...
An initial Public Offering has for decades been the endgame for an aspiring biotech company. Thinking back just 10 years, an IPO was conceivable generally only once a company had successfully brought at least one lead therapeutic into late-stage clinical trials and the pipeline was robust. Today this has changed...
In late spring when apple trees are filled with young fruits, the best way to ensure a healthy harvest in autumn is to thin out the fruits, which in turn strengthens the tree and helps the remaining fruits grow and ripen.In late spring when apple trees are filled with young fruits, the best way to ensure a healthy harvest in autumn is to thin out the fruits, which in turn strengthens the tree and helps the remaining fruits grow and ripen.While the gardener knows that the autumn harvest will be stronger for doing it, the thinning out process is painful every time...
For most emerging bio-pharma or medtech companies, establishing a development or commercialization partnership is a core component of their strategic plan, and, sealing the deal is cause for much celebration. While hard work and a number of all-nighters may go into signing an agreement, ensuring the partnership achieves its objectives and sails across the finish line is often harder, and often a bumpy ride...
The majority of pharma and biotech venture creations are aimed at one or both of two fundamental objectives, bringing a novel therapeutic to patients and generating returns for their founders and investors. Often, pathways are poorly understood by the bootstrap team, and professional “help” is being sought from incubators, boards, investors and advisors, embedding possibly conflicting perspectives and goals into the core fabric of the company.
There are two predominantly emerging therapeutic strategies for the development of drugs to treat patients with COVID-19. The first is to target the virus (SARS-CoV2) itself. This is how Remdesivir, the most widely discussed treatment for COVID-19 works. The second therapeutic strategy is to mitigate the effect of cytokine...
The world of healthcare has been turned upside down. The COVID-19 pandemic has taken healthcare systems across the globe to breaking point, with hospitalization rates never before seen and hundreds of thousands of fatalities. While the immediate crisis was characterized by lack of personal protective equipment...
Drug development is like climbing a well-defined heavily regulated “ladder”. This ladder has and will always rightly hold the safety of patients subjected to experimental therapies as its number one priority. Each of the steps are clearly defined, and whilst some may intertwine generally include..
By the very nature of the profession, doctors become “good doctors” by developing strong entrepreneurship qualities. Running an own private practice or being part of a large group practice, each provides for taking on sizable risk and executing resource allocation tasks where one must embody strong communication qualities to see positive outcomes...
Running a healthy efficient business is a full-time task for senior management during normal times. The unprecedented transition into a world of uncertainty, paired with unclear timing and nature of recovery, present not only new challenges to navigate but also an unprecedented volume of forced “restructuring” in our industry...
Whilst Corona virus news are out there loud and clear, a mindset of “I would survive hence will be taking my chance” made us pause and reply, calmly, that yes you likely would but could carry it to those who would not – and that is the problem. We point out the often quoted comparison of 1918 flu epidemic responses between the two cities...
Treehill Partners operates extensive Healthcare Investment Banking services and world class biotechnology Strategy Consulting as well as Leadership Support advisory services to some of today’s most innovative industry leadership teams. Over the years, as we evaluate investment proposals put forward to corporates, venture capitalists...

Subscribe to our mailings!

Thank You

Please choose your subscriptions:

Unsubscribe any time using the footer of our emails. For information about our privacy practices, please visit our privacy policy.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.